Complement activation by injectable colloidal drug carriers

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 187-230

  Passirani, Catherine ^a   Benoît, Jean Pierre ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056349819     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (171)

1. Muller-Eberhard, H. J., Molecular organization and function of the complement system. Annu. Rev. Biochem., 1988; 57: 321-347.
2. Cooper, N. R., The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol., 1985; 37: 151-216.
3. Ziccardi, R. J., A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol., 1982; 128: 2505-2508.
4. Loos, M., and Heinz, H. P., Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes. Acta Pathol. Microbiol. Immunol. Scand. Suppl., 1984; 284: 67-74.
5. Pangburn, M. K., Schreiber, R. D., Muller-Eberhard, H. J., Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med., 1981; 154: 856-867.
6. Medicus, R. G., Gotze O., and Muller-Eberhard, H. J., Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med., 1976; 144: 1076-1093.
7. Nilsson, B., and Nilsson, U. R., SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation. Immunol. Lett., 1986; 13: 11-14.
8. Medof, M. E. et al., Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med., 1987; 165: 848-864.
9. Muller-Eberhard, H. J., The membrane attack complex of complement. Annu. Rev. Immunol., 1986; 4: 503-528.
10. Ishida, T., Harashima H., Kiwada, H., Liposome clearance. Biosci. Rep., 2002; 22: 197-224.
11. Schreiber, R. D., Morrison, D. C., Podack, E. R., and Muller-Eberhard, H. J., Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J. Exp. Med., 1979; 149: 870-882.
12. Schreiber, R. D., The chemistry and biology of complement receptors. Springer Semin. Immunopathol., 1984; 7: 221-249.
13. Medof, M. E., Iida, K., Mold, C., and Nussenzweig, V., Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J. Exp. Med., 1982; 156: 1739-1754.
14. Haeffner-Cavaillon, N., Cavaillon, J. M., Laude, M., and Kazatchkine, M. D., C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J. Immunol., 1987; 139: 794-799.
15. Schulman, E. S., Post, T. J., Henson, P. M., and Giclas, P. C., Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J. Clin. Invest., 1988; 81: 918-923.
16. Johnson, A. R., Hugli, T. E., Muller-Eberhard, H. J., Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology, 1975; 28:1067.
17. Williams, D. F., Tissue-biomaterial interactions. J. Mater. Sci., 1987; 22: 3421-3445.
18. Cooper, P. D., Solid phase activators of the alternative pathway of complement and their use in vivo. In: Sims, R. B. (ed.). Activators and Inhibitors of Complement. Kluwer Academic Publishers, The Netherlands, 1993, pp. 69-106.
19. Kazatchkine, M. D., and Carreno, M. P., Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials, 1988; 9: 30-35.
20. Richards, R. L., Gewurz, H., Siegel, J., and Alving, C. R., Interactions of C-reactive protein and complement with liposomes. II. Influence of membrane composition. J. Immunol., 1979; 122: 1185-1189.
21. Mold, C. et al., Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J. Immunol., 1981; 126: 856-860.
22. Kovacsovics, T., Tschopp, J., Kress, A., and Isliker, H., Antibody-independent activation of C1, the first component of complement, by cardiolipin. J. Immunol., 1985; 135: 2695-2700.
23. Chonn, A., Cullis, P. R., and Devine, D. V., The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol., 1991; 146: 4234-4241.
24. Fries, L. F., Gaither, T. A., Hammer, C. H., Frank, M. M., C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med, 1984; 160: 1640-1655.
25. Lutz, H. U. et al., Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc. Natl. Acad. Sci. USA, 1987; 84: 7368-7372.
26. Hunter, R. L., and Bennett, B., The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol., 1984; 133: 3167-3175.
27. Szebeni, J., Muggia, F. M., and Alving, C. R., Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst., 1998; 90: 300-306.
28. Alving, C. R., and Swartz, G. M., Jr., Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit. Rev. Immunol., 1991; 10: 441-453.
29. Fearon, D. T., Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA, 1978; 75: 1971-1975.
30. Kazatchkine, M. D., Fearon, D. T., Silbert, J. E., and Austen, K. F., Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J. Exp. Med., 1979; 150: 1202-1215.
31. Pain, D., Das, P. K., Ghosh, P. C., and Bachhawat, B. K., Increased circulatory half-life of liposomes after conjunction with dextran. J. Biosci., 1984; 6: 811-816.
32. Von Zabern, I., Action of polyionic substances on the complement system. In: Sims, R. B. (ed.), Activators and Inhibitors of Complement. Kluwer Academic Publishers, The Netherlands, 1993, pp. 149-165.
33. Carreno, M. P., Labarre, D., Jozefowicz, M., and Kazatchkine, M. D., The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. Mol. Immunol., 1988; 25: 165-171.
34. Toufik, J., and Labarre, D., Relationship between reduction of complement activation by polysaccharide surfaces bearing diethylaminoethyl groups and their degree of substitution. Biomaterials, 1995; 16: 1081-1088.
35. Montdargent, B., Labarre, D., Jozefowicz, M., Interactions of functionalized polystyrene derivatives with the complement system in human serum. J. Biomater. Sci. Polym. Ed., 1991; 2: 25-35.
36. Montdargent, B. et al., Regulation by sulphonate groups of complement activation induced by hydroxymethyl groups on polystyrene surfaces. Biomaterials, 1993; 14: 203-208.
37. Carreno, M. P. et al., Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. Biomaterials, 1988; 9: 514-518.
38. Maillet, F., and Kazatchkine, M. D., Specific antibodies enhance alternative complement pathway activation by cuprophane. Nephrol. Dial. Transplant., 1991; 6: 193-197.
39. Videm, V., and Mollnes, T. E., Human complement activation by polygeline and dextran 70. Scand. J. Immunol., 1994; 39: 314-320.
40. Meri, S., and Pangburn, M. K., Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA, 1990; 87: 3982-3986.
41. Pangburn, M. K. et al., Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J. Immunol., 2000; 164: 4742-4751.
42. Meri, S., and Pangburn, M. K., Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun., 1994; 198: 52-59.
43. Weiler, J. M., Yurt, R. W., Fearon, D. T., and Austen, K. F., Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. Exp. Med., 1978; 147: 409-421.
44. Kazatchkine, M. D. et al., Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J. Clin. Invest., 1981; 67: 223-228.
45. Maillet, F., and Petitou, M., Choay, J., and Kazatchkine, M. D., Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol. Immunol. 1988; 25: 917-923.
46. Nilsson, U. R., Storm, K. E., Elwing, H., and Nilsson, B., Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol. Immunol., 1993; 30: 211-219.
47. Nilsson, U. R. et al., Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand. J. Immunol., 1993; 37: 349-354.
48. Gobel, R. J., Janatova, J., Googe, J. M., and Apple, D. J., Activation of complement in human serum by some synthetic polymers used for intraocular lenses. Biomaterials, 1987; 8: 285-288.
49. Pekna, M. et al., Complement activation by polymethyl methacrylate minimized by end-point heparin attachment. Biomaterials, 1993; 14: 189-192.
50. Mollnes, T. E. et al., A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs, 1995; 19: 909-917.
51. Harig, F. et al., Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac. Cardiovasc. Surg., 1999; 47: 111-118.
52. Heyer, E. J. et al., Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J. Cardiothorac. Vasc. Anesth., 2002; 16: 37-42.
53. Ovrum, E. et al., High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann. Thorac. Surg., 1995; 60: 1755-1761.
54. Weiler, J. M., Edens, R. E., Linhardt, R. J., and Kapelanski, D. P., Heparin and modified heparin inhibit complement activation in vivo. J. Immunol., 1992; 148: 3210-3215.
55. Mauzac, M., Maillet, F., Jozefonvicz, J., Kazatchkine, M. D., Anticomple-mentary activity of dextran derivatives. Biomaterials, 1985; 6: 61-63.
56. Blondin, C. et al., Relationships between chemical characteristics and anti-complementary activity of fucans. Biomaterials, 1996; 17: 597-603.
57. Blondin, C. et al., Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol. Immunol., 1994; 31: 247-253.
58. Tissot, B. et al., Interaction of fucoidan with the proteins of the complement classical pathway. Biochim. Biophys. Acta., 2003; 1651: 5-16.
59. Weisman, H. F. et al., Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science, 1990; 249: 146-151.
60. Barratt, G. M., Therapeutic applications of colloidal drug carriers. Pharm. Sci. Technol. Today, 2000; 3: 163-171.
61. Senior, J., and Gregoriadis, G., Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett., 1982; 145: 109-114.
62. Moghimi, S. M., Hunter, A. C., and Murray, J. C., Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001; 53: 283-318.
63. Patel, H. M., Moghimi, S. M., Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system—The concept of tissue specificity. Adv. Drug Deliv. Rev., 1998; 32: 45-60.
64. Moghimi, S. M., Patel, H. M., Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. Biochim. Biophys. Acta, 1989; 984: 384-387.
65. Moghimi, S. M., Patel, H. M., Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim Biophy. Acta, 1989; 984: 379-383.
66. Ogawara, K., et al., Interaction of polystyrene microspheres with liver cells: roles of membrane receptors and serum proteins. Biochim. Biophys. Acta, 1999; 1472: 165-172.
67. Moghimi, S. M., et al., Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J. Leukoc. Biol, 1993; 54: 513-517.
68. Moghimi, S. M., and Szebeni, J., Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003; 42: 463-478.
69. Schiffelers, R. M., Storm, G., and Bakker-Woudenberg, I. A., Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm. Res., 2001; 18: 780-787.
70. Abe, T. et al., Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int. J. Cancer, 1997; 74: 245-250.
71. Ahsan, F., Rivas, I. P., Khan, M. A., and Torres Suarez, A. I., Targeting to macrophages: role of physicochemical properties of particulate carriers— liposomes and microspheres—on the phagocytosis by macrophages. J. Control Release, 2002; 79: 29-40.
72. Seyler, I., et al., Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int. J. Immunopharmacol., 1996; 18: 385-392.
73. Gregoriadis, G., The immunological adjuvant and vaccine carrier properties of liposomes. J. Drug Target, 1994; 2: 351-356.
74. Boeckler, C. et al., Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur. J. Immunol., 1999; 29: 2297-2308.
75. Gregoriadis, G., Saffie, R., and Hart, S. L., High yield incorporation of plasmid DNA within liposomes: effect on DNA integrity and transfection efficiency. J. Drug Target, 1996; 3: 469-475.
76. Frank, M. M., and Fries, L. F., The role of complement in inflammation and phagocytosis. Immunol. Today, 1991; 12: 322-326.
77. Maeda, H., et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release, 2000; 65: 271-284.
78. Moghimi, S. M., et al., An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta, 1993; 1157: 233-240.
79. Klibanov, A. L. et al., Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta, 1991; 1062: 142-148.
80. Moghimi, S. M., and Bonnemain, B., Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv. Drug Deliv. Rev., 1999; 37: 295-312.
81. Litzinger, D. C., Buiting, A. M., van Rooijen, N., Huang, L., Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta, 1994; 1190: 99-107.
82. Stolnik, S., Illum, L., Davis, S., Long-circulating microparticulate drug carriers. Adv. Drug Deliv. Rev, 1995; 16: 195-214.
83. Roerdink, F., Regts, J., Van Leeuwen, B., and Scherphof, G., Intrahepatic uptake and processing of intravenously injected small unilamellar phospholipid vesicles in rats. Biochim. Biophys. Acta, 1984; 770: 195-202.
84. Romero, E. L. et al., On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett., 1999; 448: 193-196.
85. Scherphof, G. L., and Kamps, J. A., The role of hepatocytes in the clearance of liposomes from the blood circulation. Prog. Lipid Res., 2001; 40: 149-166.
86. Quellec, P. et al., Protein encapsulation within poly(ethylene glycol)-coated nanospheres. II. Controlled release properties. J. Biomed. Mater. Res., 1999; 47: 388-395.
87. Li, Y. et al., PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control Release, 2001; 71: 203-211.
88. Kircheis, R. et al., Tumor targeting with surface-shielded ligand—polycation DNA complexes. J. Control Release, 2001; 72: 165-170.
89. Zambaux, M. F. et al., Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. Int. J. Pharm., 2001; 212: 1-9.
90. Zambaux, M. F. et al., Preparation and characterization of protein C-loaded PLA nanoparticles. J. Control Release, 1999; 60: 179-188.
91. Couvreur, P. et al., Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carrier Syst., 2002; 19: 99-134.
92. Barratt, G., Colloidal drug carriers: achievements and perspectives. Cell Mol. Life Sci, 2003; 60: 21-37.
93. Liu, F., and Huang, L., Development of non-viral vectors for systemic gene delivery. J. Control Release, 2002; 78: 259-266.
94. Bhadra, D., Bhadra, S., Jain, P., and Jain, N. K., Pegnology: a review of PEG-ylated systems. Pharmazie, 2002; 57: 5-29.
95. Lee, J. H., Kopecek, J., and Andrade, J. D., Protein-resistant surfaces prepared by PEO-containing block copolymer surfactants. J. Biomed. Mater. Res., 1989; 23: 351-368.
96. Jeon, S. I., Lee, J. H., Andrade, J. D., and De Gennes, P. G., Protein-surface interactions in the presence of polyethylene oxide I. Simplified theory. J. Coll. Interface Sci., 1991; 142: 149-158.
97. Torchilin, V., and Trubetskoy, V., Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev., 1995; 16: 141-155.
98. Torchilin, V. P., Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul., 1998; 15: 1-19.
99. Torchilin, V. P. et al., Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta, 1994; 1195: 11-20.
100. Bergstrom, K. et al., Effects of branching and molecular weight of surface-bound poly(ethylene oxide) on protein rejection. J. Biomater. Sci. Polym. Ed., 1994; 6: 123-132.
101. Woodle, M. C., Controlling liposome blood clearance by surface-grafted polymers. Adv. Drug. Deliv. Rev., 1998; 32: 139-152.
102. Kedar, E. et al., Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. Emphasis Tumor Immunol., 1994; 16: 47-59.
103. Woodle, M. C. et al., Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm. Res., 1992; 9: 260-265.
104. Gombotz, W. R., Wang, G. H., Horbett, T. A., and Hoffman, A. S., Protein adsorption to poly(ethylene oxide) surfaces. J. Biomed. Mater. Res., 1991; 25: 1547-1562.
105. Jeon, S. I., Lee, J. H., Andrade, J. D., and De Gennes, P. G., Protein-surface interactions in the presence of polyethylene oxide. II Effect of protein size. J. Coll. Interface Sci., 1991; 142: 159-166.
106. Li, J., Caldwell, K., and Rapoport, N., Surface properties of Pluronic-coated polymeric colloids. Langmuir, 1994; 10: 4475-4482.
107. Bazile, D. et al., Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci., 1995; 84: 493-498.
108. Gref, R. et al., The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev., 1995; 16: 215-233.
109. Mosqueira, V. C. et al., Interactions between a macrophage cell line (J774A1) and surface-modified poly (D, L-lactide) nanocapsules bearing poly(ethylene glycol). J. Drug Target, 1999; 7: 65-78.
110. Peracchia, M. T. et al., Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control Release, 1999; 60: 121-128.
111. Peracchia, M. T. et al., Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials, 1999; 20: 1269-1275.
112. Peracchia, M. T. et al., Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci., 1997; 61: 749-761.
113. De Jaeghere, F. et al., Cellular uptake of PEO surface-modified nanoparticles: evaluation of nanoparticles made of PLA:PEO diblock and triblock copolymers. J. Drug Target, 2000; 8: 143-153.
114. Remes, A., and Williams, D. F., Immune response in biocompatibility. Biomaterials, 1992; 13: 731-743.
115. Fournier, E., Passirani, C., Montero-Menei, C. N., Benoit, J. P., Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials, 2003; 24: 3311-3331.
116. Lim, Y. B. et al., Biodegradable polyester, poly[alpha-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene carrier. Pharm. Res., 2000; 17: 811-816.
117. Pedone, E. et al., alpha, beta-poly(asparthylhydrazide)-glycidyltrimethylammo-nium chloride copolymers (PAHy-GTA): novel polymers with potential for DNA delivery. J. Control Release, 2001; 77: 139-153.
118. Bazile, D. V. et al., Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials, 1992; 13: 1093-1102.
119. Kamei, S., and Kopecek, J., Prolonged blood circulation in rats of nanospheres surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacryla-mide]. Pharm. Res., 1995; 12: 663-668.
120. Gaur, U. et al., Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm., 2000; 202: 1-10.
121. van Oss, C. J., Phagocytosis as a surface phenomenon. Annu. Rev. Microbiol., 1978; 32: 19-39.
122. Alcami, A., and Koszinowski, U. H., Viral mechanisms of immune evasion. Immunol. Today, 2000; 21: 447-455.
123. Gabizon, A., and Papahadjopoulos, D., The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta, 1992; 1103: 94-100.
124. Gregoriadis, G., McCormack, B., Wang, Z., and Lifely, R., Polysialic acids: potential in drug delivery. FEBS Lett., 1993; 315: 271-276.
125. Olivier, J. et al., Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. J. Control Release, 1996; 40: 157-168.
126. Maruyama, A. et al., Nanoparticle DNA carrier with poly(L-lysine) grafted polysaccharide copolymer and poly(D, L-lactic acid). Bioconjug. Chem., 1997; 8: 735-742.
127. Passirani, C. et al., Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). J. Biomater. Sci. Polym. Ed, 1999; 10: 47-62.
128. Passirani, C., Barratt, G., Devissaguet, J. P., Labarre, D., Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sci., 1998; 62: 775-785.
129. Jaulin, N. et al., Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Drug Target, 2000; 8: 165-172.
130. Passirani, C., Barratt, G., Devissaguet, J. P., Labarre, D., Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res., 1998; 15: 1046-1050.
131. Osterberg, E. et al., Protein-rejecting ability of surface-bound dextran in end-on and side-on configurations: comparison to PEG, J. Biomed. Mater. Res., 1995; 29: 741-747.
132. Wang, S., and Low, P. S., Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J. Control Release, 1998; 53: 39-48.
133. Zalipsky, S. et al., Biologically active ligand-bearing polymer-grafted liposomes. In: Gregoriadis GaMC, B. (ed.), Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems. Plenum Press, New York, 1998, pp. 131-138.
134. Mercadal, M. et al., A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains. Biochim. Biophys. Acta, 1999; 1418: 232-238.
135. Park, J. W. et al., Tumor targeting using anti-her2 immunoliposomes. J. Control Release, 2001; 74: 95-113.
136. Szebeni, J., Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug. Carrier Syst., 2001; 18: 567-606.
137. Gestin, J. F. et al., Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J. Nucl. Med., 2001; 42: 146-153.
138. Allemann, E. et al., Kinetics of blood component adsorption on poly(D, L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J. Biomed. Mater Res., 1997; 37: 229-234.
139. Nilsson, U. R., and Nilsson, B., Simplified assays of hemolytic activity of the classical and alternative complement pathways. J. Immunol. Methods, 1984; 72: 49-59.
140. Vittaz, M. et al., Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials, 1996; 17: 1575-1581.
141. Von Zabern, I., Drugs and low molecular weights compounds affecting the complement system. In: Sims, R. B. (ed.), Activators and Inhibitors of Complement. Kluwer Academic Publishers, The Netherlands, 1993, pp. 137-148.
142. Szebeni, J. et al., Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion, 1997; 37: 150-159.
143. Szebeni, J. et al., The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol., 2003; 373: 136-154.
144. Volanakis, J. E., and Wirtz, K. W., Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature, 1979; 281: 155-157.
145. Bradley, A. J., and Devine, D. V., The complement system in liposome clearance: Can complement deposition be inhibited? Adv. Drug Deliv. Rev., 1998; 32: 19-29.
146. Wassef, N. M. et al., Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J. Immunol., 1989; 143: 2990-2995.
147. Devine, D. V. et al., Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim. Biophys. Acta, 1994; 1191: 43-51.
148. Harashima, H. et al., Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism. Pharm. Res., 1996; 13: 1049-1054.
149. Senior, J. H., Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst., 1987; 3: 123-193.
150. Harashima, H., Sakata, K., Funato, K., and Kiwada, H., Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res., 1994; 11: 402-406.
151. Harashima, H. et al., Synergistic effect between size and cholesterol content in the enhanced hepatic uptake clearance of liposomes through complement activation in rats. Pharm. Res., 1996; 13: 1704-1709.
152. Marjan, J., Xie, Z., and Devine, D. V., Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim. Biophys. Acta, 1994; 1192: 35-44.
153. Dams, E. T. et al., Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 2000; 292: 1071-1079.
154. Laverman, P. et al., Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 2001; 298: 607-612.
155. Laverman, P., Carstens, M. G., Storm, G., and Moghimi, S. M., Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim. Biophys. Acta, 2001; 1526: 227-229.
156. Ishida, T. et al., Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control Release, 2003; 88: 35-42.
157. Price, M. E., Cornelius, R. M., and Brash, J. L., Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim. Biophys. Acta, 2001; 1512: 191-205.
158. Woodle, M. C., and Lasic, D. D., Sterically stabilized liposomes. Biochim. Biophys. Acta, 1992; 1113: 171-199.
159. Gbadamosi, J. K., Hunter, A. C., and Moghimi, S. M., PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett., 2002; 532: 338-344.
160. Ameller, T. et al., Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharm. Res., 2003; 20: 1063-1070.
161. Mosqueira, V. C. et al., Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials, 2001; 22: 2967-2979.
162. Ogawara, K. et al., Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J. Control Release, 2001; 77: 191-198.
163. Labarre, D. et al., Complement activation by substituted polyacrylamide hydrogels for embolisation and implantation. Biomaterials, 2002; 23: 2319-2327.
164. Chenoweth, D. E., Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. Artif. Organs, 1984; 8: 281-290.
165. Chauvierre, C., Labarre, D., Couvreur, P., and Vauthier, C., Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res, 2003; 20: 1786-1793.
166. Szebeni, J. et al., Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation, 1999; 99: 2302-2309.
167. Ingram, D. A., Forman, M. B., and Murray, J. J., Activation of complement by Fluosol attributable to the pluronic detergent micelle structure. J. Cardiovasc. Pharmacol., 1993; 22: 456-461.
168. Gabizon, A., Muggia, F. M., In: Storm, G. (ed.), Long-circulating Liposomes: Old Drugs, New Therapeutics. Springer-Verlag and Landes Bioscience, New York, 1998, pp. 155-174.
169. Gordon, D. L., Johnson, G. M., and Hostetter, M. K., Ligand-receptor interactions in the phagocytosis of virulent Streptococcus pneumoniae by polymorphonuclear leukocytes. J. Infect. Dis., 1986; 154: 619-626.
170. Wilkinson, B. J., Peterson, P. K., and Quie, P. G., Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers. Infect. Immun., 1979; 23: 502-508.
171. Cornacoff, J. B. et al., Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest., 1983; 71: 236-247.